John H. Holcombe

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

David C. Klonoff, John B. Buse, Loretta L. Nielsen et al. · Current Medical Research and Opinion · 2007 · 698 citations

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

Ralph A. DeFronzo, Ted Okerson, Prabhakar Viswanathan et al. · Current Medical Research and Opinion · 2008 · 373 citations

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials

John B. Buse, David C. Klonoff, Loretta L. Nielsen et al. · Clinical Therapeutics · 2007 · 278 citations

Obesity, Metabolic Syndrome, Interim Analysis +10

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

David C. Klonoff, John B. Buse, Loretta L. Nielsen et al. · Current Medical Research and Opinion · 2008 · 227 citations

Obesity, Metabolic Syndrome, Diabetes Management +9

Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes

Julio Rosenstock, Leslie J. Klaff, Sherwyn Schwartz et al. · Diabetes Care · 2010 · 226 citations · Full text